Patent classifications
C12N2760/18871
OPTIMIZED HIV ENVELOPE GENE AND EXPRESSION THEREOF
The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
Anticancer agent comprising HVJ-E and immune checkpoint protein inhibitor
The present invention provides an anticancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) an inhibitor of an immune checkpoint protein.
Optimized HIV envelope gene and expression thereof
The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
Anti-cancer agent comprising HVJ-E and CXCL2
The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.
ANTICANCER AGENT COMPRISING HVJ-E AND IMMUNE CHECKPOINT PROTEIN INHIBITOR
The present invention provides an anticancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) an inhibitor of an immune checkpoint protein.
OPTIMIZED HIV ENVELOPE GENE AND EXPRESSION THEREOF
The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
Optimized HIV envelope gene and expression thereof
The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
ANTI-CANCER AGENT COMPRISING HVJ-E AND CXCL2
The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.
GENETICALLY STABLE REPLICATION COMPETENT SENDAI VIRUS VECTOR(S) CONTAINING AND EXPRESSING OPTIMIZED HIV GENES
The present invention relates to genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes, methods for making the same and cell substrates qualified for vaccine production which may comprise genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes.